Physician profile
Peter W Springsteen
NPI 1265438790
$623.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $95.02 · 2021: $166 · 2022: $85.27 · 2023: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $170.40 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $138.49 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $57.43 | 2020-2022 | |
| Lilly USA, LLC | $56.79 | 2019-2021 | |
| Abbvie INC. | $50.76 | 2019-2021 | |
| Glaxosmithkline, LLC. | $30.57 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.78 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $28.71 | 2021-2022 | |
| Alkermes, INC. | $17.33 | 2019 | |
| Astellas Pharma US INC | $16.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2021 | |
| Amgen INC. | $13.52 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Springsteen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.